{"id":7868,"date":"2026-01-30T14:06:04","date_gmt":"2026-01-30T14:06:04","guid":{"rendered":"https:\/\/godshand.link\/ground_post\/who-drug-information-volume-39-no-4\/"},"modified":"2026-01-30T14:06:04","modified_gmt":"2026-01-30T14:06:04","slug":"who-drug-information-volume-39-no-4","status":"publish","type":"ground_post","link":"https:\/\/godshand.link\/en_gb\/ground_post\/who-drug-information-volume-39-no-4\/","title":{"rendered":"WHO Drug Information – Volume 39, No. 4"},"content":{"rendered":"


\n<\/p>\n

\n
\n
\n
\n \"WHO
\n <\/figure>\n
Download (8.5 MB)<\/span><\/a><\/div><\/div>\n
\n
\n
\n
\n

Overview <\/h3>\n

The Fourth issue of volume 39 for 2025 includes:<\/span><\/p>\n

<\/div>\n
<\/strong><\/div>\n
Pharmaceutical News<\/strong><\/div>\n
– Thin-Layer Chromatography: A Valuable Tool in the Fight Against Substandard\/Falsified Medicines<\/div>\n
<\/div>\n
Consultation Documents<\/strong><\/div>\n
–\u00a0 \u00a0Tenofovir Alafenamide Hemifumarate (tenofoviri alafenamidi hemifumaras)<\/div>\n
–\u00a0 \u00a0Diethylcarbamazine Tablets (diethylcarbamazini compressi)<\/div>\n
–\u00a0 \u00a0Cefiderocol Powder for Concentrate for Solution for Infusion (cefiderocoli pulvis pro concentrato pro solutione pro infusione)<\/div>\n
–\u00a0 \u00a0Cefiderocol Sulfate Tosilate (cefiderocoli sulfas tosilatum)\u00a0<\/div>\n
<\/div>\n
Anatomical Therapeutic Chemical\/Defined Daily Dose (ATC\/DDD) Classification\u00a0<\/strong><\/div>\n
–\u00a0 \u00a0ATC\/DDD Classification (Temporary)<\/div>\n
–\u00a0 \u00a0ATC\/DDD Classification (Final)<\/div>\n
<\/div>\n
Volume 39, issue 4 concludes with the International Nonproprietary Names (INN) List – Proposed<\/strong>\u00a0INN List No. 134<\/strong><\/div>\n

\u00a0<\/em><\/p>\n

\u00a0<\/p>\n<\/p><\/div><\/div>\n

\n
\n
\n
WHO Team<\/div>\n
\n
\nAccess to Medicines and Health Products (MHP), <\/span>
\n
\n Health Product Policy and Standards (HPS)<\/a>, <\/span>
\n
\nINN and Classification of Medical Products (INN), <\/span>
\n
\nPrequalification (PQT), <\/span>
\n
\n Regulation and Prequalification (RPQ)<\/a>, <\/span>
\n
\nRegulation and safety (REG) <\/span>\n <\/div><\/div>\n
\n
Editors<\/div>\n
World Health Organization<\/div><\/div>\n
\n
Number of pages<\/div>\n
366<\/div><\/div>\n
\n
Reference numbers<\/div>\n
\n
ISBN: <\/strong>9789240120525<\/span><\/div><\/div><\/div>\n
\n
Copyright<\/div>\n


\n
\n
\n
\n
\n <\/a>\n <\/div><\/div><\/div><\/div><\/div><\/div>\n<\/section>\n


\n
Source link <\/a><\/p>","protected":false},"excerpt":{"rendered":"

Download (8.5 MB) Overview The Fourth issue of volume 39 for 2025 includes: Pharmaceutical News – Thin-Layer Chromatography: A Valuable Tool in the Fight Against Substandard\/Falsified Medicines Consultation Documents –\u00a0 \u00a0Tenofovir Alafenamide Hemifumarate (tenofoviri alafenamidi hemifumaras) –\u00a0 \u00a0Diethylcarbamazine Tablets (diethylcarbamazini compressi) –\u00a0 \u00a0Cefiderocol Powder for Concentrate for Solution for Infusion (cefiderocoli pulvis pro concentrato pro solutione pro infusione) –\u00a0 \u00a0Cefiderocol…<\/p>","protected":false},"author":99035,"featured_media":7869,"parent":0,"menu_order":0,"comment_status":"open","ping_status":"open","template":"","format":"standard","meta":{"give_campaign_id":0,"footnotes":""},"tags":[1572,1270,1573],"ground_category":[315,316],"class_list":["post-7868","ground_post","type-ground_post","status-publish","format-standard","has-post-thumbnail","hentry","tag-drug","tag-information","tag-volume","ground_category-2-grounds-tribulation","ground_category-2-1-time-disease"],"fifu_image_url":"https:\/\/iris.who.int\/server\/api\/core\/bitstreams\/c83fd6af-e555-471e-a74f-b2a9631d872e\/content","_links":{"self":[{"href":"https:\/\/godshand.link\/en_gb\/wp-json\/wp\/v2\/ground_post\/7868","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/godshand.link\/en_gb\/wp-json\/wp\/v2\/ground_post"}],"about":[{"href":"https:\/\/godshand.link\/en_gb\/wp-json\/wp\/v2\/types\/ground_post"}],"author":[{"embeddable":true,"href":"https:\/\/godshand.link\/en_gb\/wp-json\/wp\/v2\/users\/99035"}],"replies":[{"embeddable":true,"href":"https:\/\/godshand.link\/en_gb\/wp-json\/wp\/v2\/comments?post=7868"}],"version-history":[{"count":0,"href":"https:\/\/godshand.link\/en_gb\/wp-json\/wp\/v2\/ground_post\/7868\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/godshand.link\/en_gb\/wp-json\/wp\/v2\/media\/7869"}],"wp:attachment":[{"href":"https:\/\/godshand.link\/en_gb\/wp-json\/wp\/v2\/media?parent=7868"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/godshand.link\/en_gb\/wp-json\/wp\/v2\/tags?post=7868"},{"taxonomy":"ground_category","embeddable":true,"href":"https:\/\/godshand.link\/en_gb\/wp-json\/wp\/v2\/ground_category?post=7868"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}